India-based drugmaker Lupin has acquired 100% equity interest in Russian generic pharmaceutical firm ZAO Biocom, allowing it to expand the operations in Russian pharmaceutical market.

The deal’s terms have not yet been disclosed.

Lupin CEO Vinita Gupta said: "Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets, as well as other Eastern European markets in the future."

Founded in 1991, Biocom produces therapies for the cardiovascular and central nervous systems, as well as antimicrobials for systemic use. The company is also involved in the contract manufacturing and secondary packaging.

"Biocom produces therapies for the cardiovascular and central nervous systems."

It operates a modern European GMP compliant plant and is claimed to be one of the first Russian pharmaceutical manufacturing firms to secure an approved manufacturer status from the World Health Organisation (WHO) in 2013.

With around 118 employees, Biocom reported sales of around Rs861.2m ($15.3m) in 2014.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biocom executive officer Aleksandr Sergeyev said: "Having found, built and developed Biocom together with Igor Rudinskiy for so long, I firmly believe that the future and growth of Biocom would be best handled by the management and technology expertise that Lupin brings to table."

In May this year, Lupin acquired 100% equity interest in Brazilian pharmaceutical firm Medquímica Indústria Farmacêutica.

Lupin develops and markets different branded and generic formulations, as well as biotechnology products and active pharmaceutical ingredients (APIs).

The firm’s products are used in applications, including cardiovascular, diabetology, asthma, paediatric, central nervous system (CNS), and anti-infective.